Alireza Hanifehnezhad

Alireza Hanifehnezhad

Auto-generated profile, based on publicly available information

Alireza Hanifehnezhad

Department of Virology, Faculty of Veterinary Medicine, Ankara University, Ankara, Turkey

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in Heliyon
Verified
Journal Article
Open access
AHAlireza Hanifehnezhad
Alireza Hanifehnezhad
EKEbru Şahin Kehribar
Ebru Şahin Kehribar
SÖSıdıka Öztop
Sıdıka Öztop
ASAli Sheraz
Ali Sheraz
SKSerkan Kasırga
Serkan Kasırga
AOAykut Ozkul
Aykut Ozkul
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) recently a global pandemic with unprecedented public health, economic and social impact. The development of effective mitigation strategies, therapeutics and vaccines relies on detailed genomic and biological characterization of the regional viruses. This study was carried out to isolate SARS-CoV-2 viruses circulating in Anatolia, and to investigate virus propagation in frequently-used cells and experimental animals. We obtained two SARS-CoV-2 viruses from nasopharngeal swabs of confirmed cases in Vero E6 cells, visualized the virions using atomic force and scanning electron microscopy and determined size distribution of the particles. Viral cytopathic effects on Vero E6 cells were initially observed at 72 h post-inoculation and reached 90% of the cells on the 5th day. The isolates displayed with similar infectivity titers, time course and infectious progeny yields. Genome sequencing revealed the viruses to be well-conserved, with less than 1% diversity compared to the prototype virus. The analysis of the viral genomes, along with the available 62 complete genomes from Anatolia, showed limited diversity (up to 0.2% on deduced amino acids) and no evidence of recombination. The most prominent sequence variation was observed on the spike protein, resulting in the substitution D614G, with a prevalence of 56.2%. The isolates produced non-fatal infection in the transgenic type I interferon knockout (IFNAR−/-) mice, with varying neutralizing antibody titers. Hyperemia, regional consolidation and subpleural air accumulation was observed on necropsy, with similar histopathological and immunohistochemistry findings in the lungs, heart, stomach, intestines, liver, spleen and kidneys. Peak viral loads were detected in the lungs, with virus RNA present in the kidneys, jejunum, liver, spleen and heart. In conclusion, we characterized two local isolates, investigated in vitro growth dynamics in Vero E6 cells and identified IFNAR−/− mice as a potential animal model for SARS-CoV-2 experiments.

22 January 2025 in EMBO Molecular Medicine
Verified
Journal Article
Open access
HBHatoon Baazim
Hatoon Baazim
EKEmre Koyuncu
Emre Koyuncu
GTGürol Tuncman
Gürol Tuncman
MBM Furkan Burak
M Furkan Burak
LMLea Merkel
Lea Merkel
GHGökhan S Hotamisligil
Gökhan S Hotamisligil
Host metabolic fitness is a critical determinant of infectious disease outcomes. Obesity, aging, and other related metabolic disorders are recognized as high-risk disease modifiers for respiratory infections, including coronavirus infections, though the underlying mechanisms remain unknown. Our study highlights fatty acid-binding protein 4 (FABP4), a key regulator of metabolic dysfunction and inflammation, as a modulator of SARS-CoV-2 pathogenesis, correlating strongly with disease severity in COVID-19 patients. We demonstrate that loss of FABP4 function, by genetic or pharmacological means, reduces SARS-CoV-2 replication and disrupts the formation of viral replication organelles in adipocytes and airway epithelial cells. Importantly, FABP4 inhibitor treatment of infected hamsters diminished lung viral titers, alleviated lung damage and reduced collagen deposition. These findings highlight the therapeutic potential of targeting host metabolism in limiting coronavirus replication and mitigating the pathogenesis of infection.

20 January 2022 in Turkish Journal of Biochemistry
Verified
Journal Article
Open access
PDF file
ABAliye Bastug
Aliye Bastug
HBHurrem Bodur
Hurrem Bodur
USUrartu Seker
Urartu Seker
NFNazlıcan Filazi
Nazlıcan Filazi
OAOmer Aydos
Omer Aydos
AOAykut Ozkul
Aykut Ozkul
Background: There is a knowledge gap about the characteristics of neutralizing antibody (NAb) response in patients who recovered COVID-19. In this study, it is aimed to elucidate the factors affecting the presence and titers of antibodies up to 30-days after onset. Material and methods: A total of 129 laboratory-confirmed COVID-19 patients were enrolled. Clinical data were obtained retrospectively. SARS-CoV-2 specific NAb, IgM, and IgG antibody responses were analyzed. Results: SARS-CoV-2 specific NAb, IgM and IgG, were detected at the time of hospital discharge in 60.5%, 30.2%, and 51.9% of the patients, respectively. The median time for obtaining serum samples for antibody tests after symptoms’ onset was 11 days. The median titer of neutralizing antibody (SN 50 ) was significantly higher in severe patients (25 vs. 7.5, p=0.009). Of the 23 severe patients, 52.2% (n=12) had higher NAb titers (i.e., SN 50 ≥1:25) when compared to that in non-severe patients (OR=2.89; 95%CI=1.15–7.28, p=0.021), yet, the potential effect of follow-up time on NAb status and titers could not be ruled out. Conclusions: The presence of antibody response is not the only determinative factor for recovery. The presence and higher titers of NAb were detected more in severe patients than their non-severe counterparts. Survival analysis suggested that this difference could at least be partially explained by the length of follow-up through antibody testing (at discharge) after symptoms’ onset.

23 July 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
RARecep Erdem Ahan
Recep Erdem Ahan
AHAlireza Hanifehnezhad
Alireza Hanifehnezhad
EKEbru Şahin Kehribar
Ebru Şahin Kehribar
TOTuba Cigdem Oguzoglu
Tuba Cigdem Oguzoglu
KFKatalin Foldes
Katalin Foldes
USUrartu Seker
Urartu Seker
COVID-19 pandemic effected more than 180 million people around the globe causing more than four million deaths as of July 2021. Sars-CoV-2, the new coronavirus, has been identified as the primary cause of the infection. The number of vaccinated people is increasing however prophylactic drugs are highly demanded to ensure a secure social contact. There have been a number of drug molecules repurposed to fight against Sars-CoV-2, however the proofs for the effectiveness of these drug candidates is limited. Here we demonstrated griffithsin (GRFT), a lectin protein, to block the entry of the Sars-CoV2 into the Vero6 cell lines and IFNAR-/-mouse models by attaching to spike protein of the Sars-CoV-2. Given the current mutation frequency of the Sars-CoV-2 we believe that GRFT protein-based drugs will have a high impact in preventing the transmission both on Wuhan strain as well as any other emerging variants including delta variant causing high speed spread of COVID-19.

11 September 2026 in Scientific Reports
Verified
Journal Article
Open access
PDF file
AHAlireza Hanifehnezhad
Alireza Hanifehnezhad
SOSidika Oztop
Sidika Oztop
ETEce Tavukcuoglu
Ece Tavukcuoglu
YTYigit Tanyeri
Yigit Tanyeri
EYEkimcan Yoyler
Ekimcan Yoyler
AOAykut Ozkul
Aykut Ozkul
Platforms based on adenoviral vectors have proven their efficiency in developing vaccines and therefore can be considered potential candidates for immunization strategies against CCHFV. In this study, four replication-deficient recombinant human adenovirus serotype 5 (AdV5) vectors were engineered to express CCHFV antigens: a dual-antigen NP-P2A-Gc construct and monocistronic constructs for nucleoprotein (NP), glycoprotein complex precursor (GPC), and mature glycoprotein (Gc). Following GMP-compatible production and purification, vaccine candidates were evaluated in BALB/c mice (n = 4 per group) for immunogenicity and in IFNAR−/− mice (n = 4 per group) for protective efficacy using antigenically homologous or heterologous prime-boost regimens. Animals received priming immunization on day 0 and booster on day 28 followed by lethal CCHFV challenge (1000 TCID50) on day 42. Immune responses were characterized via ELISA, virus neutralization tests, cytokine profiling, ELISpot, and flow cytometry. Post-challenge survival, viral loads in target organs, and safety profiles were assessed. All AdV5 constructs successfully expressed the target antigens and induced rapid seroconversion, with 75–100% of animals exhibiting antibody responses after priming with a single dose. The dual-antigen formulations elicited the strongest Th1-polarized responses particularly nucleoprotein + Gc combinations with interferon-γ production more than 30-fold above baseline and preferential expansion of CD4+ T helper cells (60–70% of CD3+ populations). Neutralizing antibody titers varied across groups (80–160 arbitrary units in high responders) but did not directly correlate with survival outcomes. After lethal challenge, multiple vaccine formulations achieved 100% survival throughout the 10-day observation period, while only control groups showed no protection. All vaccinated animals demonstrated significant viral load reduction of two to four logs in liver and spleen tissues, with some achieving complete clearance of the virus. Furthermore, no off-target vector dissemination was detected in examined tissues confirming safety profile of the constructs. Immunization with adenovirus serotype 5 (AdV5) vectors expressing CCHFV antigens elicited potent humoral and cellular immune responses, conferring 100% protection against lethal viral challenge across the majority of evaluated formulations. Sterilizing immunity was observed in some animals, along with evidence that protection operates through multiple immune mechanisms including both neutralizing and non-neutralizing antibody-mediated pathways. These results strongly support further clinical development of AdV5-based CCHFV vaccines, with multiple formulation strategies showing high efficacy and providing flexibility for clinical advancement. GMP-compatible production methods have been successfully implemented for these candidates, supporting their advancement toward non-human primate studies and Phase I clinical trials.